
The following study describes a methodology to establish, control, and characterize an aerosolized bioburden within a test chamber and determine the settling rate of the bioburden.
F. Andreas Toba is Vice President, Intact Pharma Operations, MedInstill Development.

The following study describes a methodology to establish, control, and characterize an aerosolized bioburden within a test chamber and determine the settling rate of the bioburden.

Published: February 2nd 2018 | Updated: